Rchr
J-GLOBAL ID：200901021585172745
Update date: Feb. 01, 2024
Hideyuki Saya
サヤ ヒデユキ | Hideyuki Saya
Affiliation and department：
Job title：
Professor Emeritus
Other affiliations (1)：
-
Keio University
Professor
Research field (1)：
Tumor biology
Research theme for competitive and other funds (4)：
- 2021 - 2023 メチオニン代謝を基盤としたがん治療抵抗性機構の解明と新規治療標的の同定
- 2020 - 2023 がん関連線維芽細胞誘導分子機構の解明とその阻害に基づく腫瘍微小環境制御
- 2019 - 2021 癌細胞シグナル活性化因子14-3-3ζを標的とした新規膵臓癌治療薬の開発
- 2017 - 2020 Elucidation of underlyingmechanism of MKL1-mediated induction of cancer associated fibroblasts and its clinical applications
Papers (447)：
-
Takatsune Shimizu, Kiyomi Kimura, Eiji Sugihara, Sayaka Yamaguchi-Iwai, Hiroyuki Nobusue, Oltea Sampetrean, Yuji Otsuki, Yumi Fukuchi, Kaori Saitoh, Keiko Kato, et al. MEK inhibition preferentially suppresses anchorage-independent growth in osteosarcoma cells and decreases tumors in vivo. Journal of Orthopaedic Research. 2021
-
Ikue Tai-Nagara, Yukiko Hasumi, Dai Kusumoto, Hisashi Hasumi, Keisuke Okabe, Tomofumi Ando, Fumio Matsuzaki, Fumiko Itoh, Hideyuki Saya, Chang Liu, et al. Blood and lymphatic systems are segregated by the FLCN tumor suppressor. Nature Communications. 2020. 11. 1
-
Tanno N, Kuninaka S, Fujimura S, Takemoto K, Okamura K, Takeda N, Araki K, Araki M, Saya H, Ishiguro K.i. Phosphorylation of the Anaphase Promoting Complex activator FZR1/CDH1 is required for Meiosis II entry in mouse male germ cell. Scientific Reports. 2020. 10. 1. 10094-10094
-
Shono K, Yamaguchi I, Mizobuchi Y, Kagusa H, Sumi A, Fujihara T, Nakajima K, Kitazato K.T, Matsuzaki K, Saya H, et al. Downregulation of the CCL2/CCR2 and CXCL10/CXCR3 axes contributes to antitumor effects in a mouse model of malignant glioma. Scientific Reports. 2020. 10. 1
-
Koike N, Kota R, Naito Y, Hayakawa N, Matsuura T, Hishiki T, Onishi N, Fukada J, Suematsu M, Shigematsu N, et al. 2-Nitroimidazoles induce mitochondrial stress and ferroptosis in glioma stem cells residing in a hypoxic niche. Communications Biology. 2020. 3. 1
ｍore...
Return to Previous Page
